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ABSTRACT: 
Introduction: Transarterial embolization (TAE) is increasingly used in the management of renal 
angiomyolipoma (AML). The level of evidence establishing the safety and efficacy of TAE has not 
increased in parallel. 
Materials and Methods: Using the MOOSE criteria, a systematic review of transarterial 
embolization of angiomyolipoma was performed to establish procedural safety and efficacy. 
MEDLINE PubMed search revealed 1739 publications, of which 31 studies met eligibility criteria. 
Results: 524 cases of TAE of AML were included. Self-limiting post-embolization syndrome 
occurred following 35.9%. Further morbidity occurred in 6.9%. No procedural mortality was 
reported. At a mean follow-up period of 39 months, mean size reduction was 3.4 cm (-38.3% of 
AML diameter). Unplanned repeat embolization or surgery was required in 20.9% during this 
period. The most frequent indications for repeat procedures include angiomyolipoma 
revascularization (30.0%), unchanged or increasing size (22.6%), refractory or recurring symptoms 
(16.7%), and representation with acute retroperitoneal hemorrhage (14.3%). A combination of two 
or more embolic agents was used in 46.8%, ethanol monotherapy in 41.7%, coil monotherapy in 
6.2%, and foam or microparticle monotherapy in 5.2%. 
Conclusions: Transarterial embolization of angiomyolipoma demonstrates low rates of mortality 
and serious complications. Retreatment rates and size reduction at a mean follow-up duration of 39 
months are presented. Longitudinal data assessing long-term size reduction and retreatment rates 
are lacking, recommendations guiding the indications for transarterial embolization and clear 
follow-up require further longitudinal data. 
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Introduction 
 
Background 
 
Angiomyolipoma is a benign renal tumour, accounting for 0.3-3% of all renal masses.1, 2 These 
tumours are composed of blood vessels, fat and smooth muscle in varying quantities.3 
Angiomyolipomata are benign, however size increase of 0.088-0.427 cm/year is reported, and can 
result in mass effect.4, 5 Distorted vascular architecture can additionally predispose angiomyolipoma 
to active retroperitoneal hemorrhage.6 Angiomyolipoma has a prevalence of 0.02-0.1% in males, 
and 0.22-0.29% in females.7, 8 20% of patients with angiomyolipoma have TSC, an autosomal-
dominant multi-organ disorder predisposing to benign tumour formation. Amongst all patients with 
TSC, 50% develop angiomyolipoma in their lifetime.9 The remaining 80% of cases of 
angiomyolipoma are sporadic.6, 8 
 
Current Management Strategies of Angiomyolipoma  
 
Prior to 1976, 93% of sporadic angiomyolipoma were treated with open total nephrectomy.6 
Angiomyolipomata were commonly excised as a malignant renal lesion could not be excluded. 
Angiomyolipoma can now be confidently diagnosed at imaging.10 Even in cases of small or fat-poor 
angiomyolipomata, magnetic resonance imaging demonstrates a specificity of 99%.11 Many centers 
now favor transarterial embolization of angiomyolipoma, and reserve surgery for patients with 
refractory symptoms, complex renal artery anatomy, failure of embolization, and rare cases of 
diagnostic uncertainty.12 The adoption of embolization as the treatment of choice has not been 
paralleled by a strengthening of the evidence supporting its use. Small studies, primarily case series 
report embolization as the sole form of therapy has a reported success of 86-90%, with a morbidity 
of 10-17%.1, 9 It permits preservation of uninvolved renal parenchyma. This is significant in patients 
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with tuberous sclerosis, who often have bilateral or multiple renal angiomyolipomata, requiring a 
conservative approach to any renal intervention. 
 
There is a paucity of literature comparing nephrectomy and nephron-sparing surgery with 
transarterial embolization in the management of angiomyolipoma.2, 9 In the last decade, successive 
studies have established the role of chemotherapy, based on mTOR inhibitors such as sirolimus, in 
the management of patients with TSC-associated angiomyolipoma. The tumour biology in these 
patients demonstrate over-activation mTOR complex 1 (mTORC1), and mTor inhibitors have 
demonstrated size-reduction in TSC-associated angiomyolipomata.13, 14 The use of chemotherapy, 
however, is not widely employed in the more common, sporadic form of AML. Future advances 
may exploit the recently proven over-expression of selective hormonal receptors through hormonal 
regulation.15 More recently, several small case series have investigated the role of radiofrequency 
ablation (RFA), however little long term follow-up is available.16, 17 
 
Current treatment strategies are twofold. In patients with active retroperitoneal hemorrhage, or with 
a symptomatic angiomyolipoma, intervention is widely advocated.18 In 1986, Oesterling et al. 
reported AML over 4 cm were more likely to present with active retroperitoneal hemorrhage. This 
size-threshold for treatment has been widely adopted, however, it does not account for factors 
which are now known to be linked with active retroperitoneal hemorrhage. To the authors’ 
knowledge, no randomized controlled trials exists comparing embolization with placebo or with 
interventional or surgical management. Additionally, few studies employed controls or present 
long-term post-procedural follow-up data. We aimed to review the literature with the primary aim 
of establishing the morbidity and mortality of transarterial embolization, whilst assessing size-
reduction and the need for repeat procedures, to establish the safety and success of this treatment. 
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Materials and Methods 
 
A MEDLINE® search was performed to assess articles relating to renal angiomyolipoma. The 
primary endpoints were the morbidity and mortality of angiomyolipoma embolization, technical 
success of embolization, the need for repeat procedures and size reduction. All published full-text 
English language publications were included. Exclusion criteria included single patient case-
reports, studies assessing surgery only, and studies without electronic editions. Several studies 
combined contemporary case series from their institution with historical case series from the 
literature for analysis. In such publications, where data from individual studies could not be 
extracted, or was insufficiently presented to permit analysis, these publications were not 
included.11219  
 
The current literature is overwhelmingly represented by retrospective single center reviews, with 
several prospective reviews and multi-center retrospective reviews. Only one study was identified 
employing case controls, thus prohibiting quantitative synthesis and meta-analysis. Qualitative 
review was employed using the MOOSE criteria; a reporting guideline tool designed for analysis of 
observational studies in epidemiology.20 As a result of the heterogeneity of patients, outcomes and 
data collection methods, interpretation was confined to pooled descriptive analysis. 
 
Results 
 
Review of the Literature  
 
A MEDLINE search using the term renal angiomyolipoma was performed on 13th May 2013, 
returning 1739 articles. 31 studies matched eligibility criteria, including 802 patients, of which 524 
(65.3%) underwent embolization. Many of these studies additionally reported patients with 
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angiomyolipoma who underwent alternate or conservative management and were presented in the 
same series, and these 278 non-embolization patients were therefore excluded from primary 
endpoint analysis. All included studies represented Level IV evidence. The 31 included studies 
were published from 1986 to 2013, however 27 of these studies were published after the year 2000, 
accounting for 93.1% of patients. The eleven largest series included were all published since 2006.  
 
Procedural Morbidity and Mortality 
 
Mean post-embolization follow-up period was 39 months. There were no intra-procedural 
mortalities or fatal complications. In 23 studies (n=304 patients) post-procedural morbidity was 
described. Post-embolization syndrome, a self-limiting constellation of symptoms including fever, 
nausea, vomiting and pain within the first 72 hours, occurred following 35.9% of procedures 
(n=109).  Further post-procedural morbidity occurred in 6.9% of patients (n=21). This included 
non-target embolization (2.3%), respiratory complications (2.0%), abscess formation (1.6%), active 
retroperitoneal hemorrhage (1.0%), allergic reactions (0.6%), urinary retention (0.6%), urinary tract 
infections (0.3%), femoral artery damage requiring repair (0.3%) and renal artery spasm (0.3%).  
 
Treatment Success and Need for Repeat Procedures 
 
Mean technical success (complete intra-procedural occlusion of arterial inflow) was obtained in 
93.3% of embolizations. In 263 cases providing both follow-up duration and size, angiomyolipoma 
reduced by a mean 3.4 cm (-38.3%) at final follow-up averaging 39 months. Several studies 
reported individual cases where selective embolization was planned in two stages to maximize renal 
preservation where renal function was impaired, typically in the context of multiple TSC-associated 
angiomyolipoma.21, 22 All remaining procedures, however, were performed view to complete 
embolization at the first attempt. Unplanned repeat procedures were performed in 20.9% of patients 
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(n=103 of 494 cases). The indication for repeat procedure was specified in 84/103 patients, causes 
include angiomyolipoma revascularization on follow-up imaging (30.0%, n=25), unchanged or 
increasing size (22.6%, n=19), refractory or recurring symptoms (16.7%, n=14), representation with 
acute retroperitoneal hemorrhage (14.3% n=12), failure to devascularize lesion (4.8%, n=4), failure 
to control active retroperitoneal hemorrhage (4.8%, n=4), failure to identify or cannulate 
hemorrhagic vessel (4.8%, n=4), concern over malignancy (2.4%, n=2), and contrast-sensitization 
requiring postponement following corticosteroid cover (1.2%, n=1). 
 
Embolization Agent 
 
In 367 patients, the method of embolization was provided. A combination of two or more embolic 
agents was used in 172 patients (46.8%). Ethanol monotherapy was used in 153 patients (41.7%). 
Coil monotherapy was used in 23 patients (6.2%). Foam or microparticle monotherapy was used 
was used in 19 patients (5.2%). These studies typically did not provide individualized data on 
specific embolization agents. Many studies also used of different agents within the same case-
series, further limiting assessment of the efficacy of individual agents. Studies using exclusively 
ethanol monotherapy (7/31 studies) had a mean technical success of 95.5% (range 83.3%-100%), 
retreatment rate of 14.7%, morbidity of 44.9% and a mean size reduction of 2.3 cm. Studies using 
exclusively two or more agents per embolization (6/31 studies) had a mean technical success of 
95.0% (range 89%-100%), retreatment rate of 24.3%, morbidity of 26.4% and mean size reduction 
of 4.6 cm.  
 
 
 
 
Discussion 
8 
 
Transarterial Embolization as a Treatment Modality 
 
The implications of this study of transarterial embolization of angiomyolipoma are a high technical 
success (93.3%), a low retreatment rate (20.9%), and a mean size reduction of 3.4 cm. These results 
are based on mean follow-up period of 39 months, and long-term data evaluating retreatment rate 
and sustained size-reduction are lacking. Selected small studies with longer follow-up have 
demonstrated increasing retreatment rates with longer follow-up. This may indicate retreatment rate 
increases over time.23  
 
Low procedural mortality (0%) compares with a 0.9% thirty-day mortality associated with 
nephrectomy.24 Embolization is associated with high rates of adverse affects (42.8%), however the 
majority are self-limiting post-embolization syndromes (35.9% of all embolizations). Routine post-
embolization syndrome prophylaxis, including antipyretics, antiemetics and analgesia may have a 
role in peri-procedural management. Several individual studies have reported lower rates of post-
embolization syndrome with super-selective embolization.23, 25 Further morbidity was uncommon, 
occurring in only 6.9% of all embolizations. This compares with 12% morbidity associated with 
partial nephrectomy for angiomyolipoma, which are typically more serious.12, 26  
 
Techniques for embolization include selective and super-selective techniques, embolizing from 
varying points within the renal arterial tree. Furthermore, there exists a variety of embolization 
techniques, including ethanol, coils, foam and microparticles, which can be employed alone or in 
combination. Several studies have compared varying size of embolic agents. It has been suggested 
that combination therapy may be most effective in reducing retroperitoneal hemorrhage, with 
microparticle embolization of the distal vascular bed to prevent retrograde filling, and coil 
occlusion of arterial inflow in an effort to both occlude perfusion and reduce arterial inflow 
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pressures.27 The small number of cases in studied case series, and presence of multiple confounding 
factors between studies, does not permit strong recommendations in favor of any one embolization 
agent at this time. 
 
Study Limitations and Bias 
 
With the exception of a single study, no case-controls were identified to assess for confounding. 
This is a fundamental weakness of case-series. Several studies completed stratified analysis, which 
can identify confounding or effect modification, however this was not performed in the majority of 
studies. An unknown source of bias was the analysis of published series reporting intervention. 
While there are papers predating intervention, there was no large, contemporary control group with 
which to compare results from patients undergoing intervention. Comparison with historical control 
groups is possible, however given advances in all aspects of patient care, this is of questionable 
applicability. Several studies evaluated procedural complications according to the Society of 
Interventional Radiology (SIR) Classification System for Complications by Outcome. Many 
studies, however, did not use such measures, and reported complications in an arbitrary or case-by-
case descriptive manner, exposing to detection bias. Due to a lack of individualized patient data, 
assessment and comparison of treatment agents is limited. Indeed, even within specific treatment 
agents, it has previously been demonstrated that even factors such as particle size of specific 
embolic material may affect outcomes.30 Attrition bias was possible as many retrospective case-
series reported the duration of follow-up, but did not specify if the end of follow-up was planned, or 
if patients were lost to follow up. The risk in individual studies varies however in the majority the 
risk of attrition bias was unclear. The short mean follow-up time is significant limitation when 
studying a slow-growing process such as angiomyolipoma. Retreatment rates at a mean of 39 
months likely underestimate the lifetime retreatment rates, and further longitudinal data are required 
to predict the long-term retreatment rate of embolization. 
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Selecting Patients Who May Benefit from Treatment 
 
The presence of symptoms, and a size exceeding 4 cm, are widely cited justifications for 
intervention.18 Current practice is based on a seminal paper from Oesterling et al, and is largely 
unchanged since 1986. In lesions less than 4 cm, only 23% of patients develop symptoms and 13% 
of cases present with active retroperitoneal hemorrhage. In lesions greater than 4 cm, this increases 
to 82% of patients presenting with symptoms, and 51% of patients presenting with active 
retroperitoneal hemorrhage.6 Our understanding of the disease biology, and the management of 
angiomyolipoma, has since changed significantly since this time, however. The use of a treatment 
size threshold of 4 cm has been examined recently by both Mourikis et al. and Dickinson et al, who 
have proposed the use of 8 cm as a size-threshold.18, 28  
 
As imaging has progressed, tumor vascularity can now be assessed, and aid in treatment decision-
making. Yamakado et al reported a significant positive association between aneurysm formation 
and active retroperitoneal hemorrhage.29 There may be a role for angiography, either conventional 
renal angiography or renal CTA, in informing treatment decisions, particularly in smaller, 
asymptomatic angiomyolipoma where surveillance may be considered.  
 
Treatment selection and timing in patients with TSC is complicated by the frequency of bilateral 
renal involvement, neurological or multi-system comorbidities, and the potential for atypical acute 
presentations. The sequela of urgent nephrectomy in a patient with multiple bilateral tumours can be 
profound, as poor or absent renal reserve may precipitate long-term renal replacement therapy.  
Pharmacological inhibition of tumor growth in these patients using mTor inhibitors may offer a 
systemic treatment for these multifocal lesions, with transarterial embolization employed for large 
angiomyolipomata, active retroperitoneal hemorrhage or symptomatic lesions. Nelson et al note the 
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rarity of acute retroperitoneal hemorrhage of angiomyolipoma in pregnancy, and suggest a 
conservative approach may be warranted during pregnancy. Where pregnancy is panned, 
prophylactic embolization may be warranted only in larger tumors.9 
 
Role for surveillance and post-procedural follow-up 
 
There is little consensus on the need, duration and modality of follow-up. In light of a retreatment 
rate of 20.9% at a mean follow-up period of 39 months, post-procedural follow-up over this period 
may be of value. The need for longer term follow-up is not clear. Clinical follow-up permits 
assessment of symptomatology, hematuria and systemic symptoms, whilst radiological follow-up 
allows assessment of size, vascularity and the presence of aneurysms. Ultrasound, CTA and 
conventional angiography have all been employed. Angiographic techniques permit the 
simultaneous assessment of both size and aneurysm formation. Ultrasound is non-invasive and 
requires no ionizing radiation or iodinated contrast, which may be of relevance in cases of renal 
impairment, as is often seen in TSC. Ultrasound has limited sensitivity of dedicated angiographic 
studies in the detection of aneurysm formation, however. A combination of radiological modalities 
and periodic clinical follow-up may be optimal following embolization. 
 
Conclusion 
 
TAE is associated with low procedural mortality (0%). Post-embolization syndrome is common 
(35.9%), and routine prophylaxis may be appropriate. Other forms of morbidity occur in 6.9%. 
Repeat embolization or surgery was required in 20.9% of cases. Mean follow-up duration remains 
short (39 months), and long-term follow-up data are required.   
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AML = Angiomyolipoma 
TAE = Transarterial Embolization 
TSC = Tuberous Sclerosis Complex 
CTA = Computed Tomography (CT) Angiography 
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